Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks The application for marketing authorization for subcutaneous ...

BioArctic AB (BRCTF) reports robust financial performance and advances in Alzheimer's treatment, while navigating market access hurdles and rising operational costs.

STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which ...

BioArctic AB, a public Swedish biopharma company, recently announced that they received allowance of a patent application directed to a method of promoting axonal regeneration using a biodegradable ...

Comments from the CEO, '2025 was a record year for BioArctic, with an operating profit of more than SEK 1.2 billion' 2025 was a fantastic year for BioArctic, with record financial results, another ...

BioArctic AB (publ), a Swedish research-based biopharma company, announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately ...

Q1 2026 Earnings Call May 20, 2026 3:30 AM EDTCompany ParticipantsGunilla Osswald - President & CEOJohanna Fälting - ...

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson's disease – AbbVie – is ducking out of the challenge. The pharma company has ...

STOCKHOLM, Feb. 13, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase 1/2 study now has been treated with ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review ...

The U.S. FDA’s three month extension of its review for Leqembi Iqlik has pushed a key regulatory decision further out, putting BioArctic (OM:BIOA B) back in focus for Alzheimer’s focused investors.